Evidence map›Paper›PMID 39280271›Full record

ArticleNarra J2024

Transcriptomic analysis of profibrinolytic and fibrinolytic inhibitor genes in COVID-19 patients.

Ika K Febrianti, Andani E Putra, Raveinal Raveinal, Aisyah Elliyanti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Narra J, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ika K FebriantiDoctoral Program of Biomedical, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.
Andani E PutraDepartment of Microbiology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.
Raveinal RaveinalDr. M. Djamil General Hospital, Padang, Indonesia.
Aisyah ElliyantiDr. M. Djamil General Hospital, Padang, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunopathogenesis of COVID-19 infection is initiated by the entry of the SARS-CoV-2 virus into the human body through droplets, entering the lungs and binding to the ACE-2 receptor. Activated macrophages stimulate an immune and inflammatory response, leading to the activation of the coagulation cascade, including profibrinolytic and fibrinolytic inhibitor processes. One of the proteins involved in profibrinolytic is encoded by the

Indexed as

COVID-19Plasminogen Activator Inhibitor 1Cross-Sectional StudiesFemaleFibrin Fibrinogen Degradation ProductsGene Expression ProfilingHumansMaleMiddle AgedReceptors, Urokinase Plasminogen ActivatorSARS-CoV-2Severity of Illness IndexTranscriptomeFibrin Fibrinogen Degradation Productsfibrin fragment DPlasminogen Activator Inhibitor 1PLAUR protein, humanReceptors, Urokinase Plasminogen ActivatorSERPINE1 protein, humanCOVID-19D-dimerfibrinolytic inhibitorprofibrinolyticTranscriptomic

Identifiers

PMID39280271
PMCPMC11391964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.